



EFFECTIVE DATE: 05|01|2017
POLICY LAST UPDATED: 07|16|2020

OVERVIEW

Low-level laser therapy (LLLT), also called photobiomodulation, is being evaluated to treat various conditions including oral mucositis, myofascial pain, joint pain, lymphedema, and chronic wounds.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

BlueCHiP for Medicare

Low-level laser therapy is covered for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation.

Low-level laser therapy is not covered for all other indications, as the evidence is insufficient to determine the effects of the technology on health outcomes, including but not limited to:

- Carpal tunnel syndrome
- Neck pain
- Subacromial impingement
- Adhesive capsulitis
- Temporomandibular joint pain
- Low back pain
- Osteoarthritic knee pain
- Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
- Rheumatoid arthritis
- Bell palsy
- Fibromyalgia
- Wound healing
- Lymphedema

Commercial Products

Low-level laser therapy is covered for prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation.

Low-level laser therapy is not medically necessary for all other indications, as the evidence is insufficient to determine the effects of the technology on health outcomes, including but not limited to:

- Carpal tunnel syndrome
- Neck pain

- Subacromial impingement
- Adhesive capsulitis
- Temporomandibular joint pain
- Low back pain
- Osteoarthritic knee pain
- Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
- Rheumatoid arthritis
- Bell palsy
- Fibromyalgia
- Wound healing
- Lymphedema

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

Low-level laser therapy (LLLT) refers to the use of red-beam or near-infrared lasers with a wavelength between 600 and 1000 nm and power between 5 and 500 MW. In contrast, lasers used in surgery typically use 300 Watts. When applied to the skin, LLLT produces no sensation and does not burn the skin. Because of the low absorption by human skin, it is hypothesized that the laser light can penetrate deeply into the tissues where it has a photobiostimulative effect. The exact mechanism of its effect on tissue healing is unknown; hypotheses have included improved cellular repair and stimulation of the immune, lymphatic, and vascular systems. LLLT is being evaluated to treat a wide variety of conditions, including soft tissue injuries, myofascial pain, tendinopathies, nerve injuries, and joint pain. LLLT has also been evaluated for lymphedema.

ORAL MUCOSITIS

Oral mucositis describes inflammation of the oral mucosa and typically manifests as erythema or ulcerations that appear 7 to 10 days after initiation of high-dose cancer therapy. Oral mucositis can cause significant pain and increased risk of systemic infection, dependency on total parenteral nutrition, and use of narcotic analgesics.

Treatment

Treatment planning may also need to be modified due to dose-limiting toxicity. There are a number of interventions for oral mucositis that may partially control symptoms, but none is considered a criterion standard treatment. When uncomplicated by infection, oral mucositis is self-limited and usually heals within 2 to 4 weeks after cessation of cytotoxic chemotherapy. Low-level laser therapy (LLLT) has been used in cancer therapy-induced oral mucositis in patients treated with radiotherapy and/or chemotherapy and hematopoietic cell transplantation.

MUSCULOSKELETAL AND NEUROLOGIC DISORDERS

Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and the most commonly performed surgery of the hand. The syndrome is related to the bony anatomy of the wrist. The carpal tunnel is bound dorsally and laterally by the carpal bones and ventrally by the transverse carpal ligament. Through this contained space run the 9 flexor tendons and the median nerve. Therefore, any space-occupying lesion can compress the median nerve and produce the typical symptoms of CTS - pain, numbness, and tingling in the distribution of the median nerve. Symptoms of more severe cases include hypesthesia, clumsiness, loss of dexterity, and weakness of pinch. In the most severe cases, patients experience marked sensory loss and significant functional impairment with thenar atrophy.

Treatment

Mild-to-moderate cases of CTS are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs, and steroid injections into the carpal tunnel itself. Patients who do not respond to conservative therapy or who present with severe CTS with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach. LLLT is also used to treat CTS.

For individuals who have increased risk of oral mucositis due to some cancer treatments (eg, chemotherapy, radiotherapy) and/or hematopoietic cell transplantation who receive LLLT, the evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

The evidence for LLLT is insufficient to determine the effects of the technology on health outcomes in individuals who have the following conditions:

- orthopedic pain (ie, neck pain, osteoarthritic knee pain, low back pain, carpal tunnel syndrome)
- shoulder conditions (eg, subacromial impingement syndrome, adhesive capsulitis), heel pain, or temporomandibular joint pain
- bone, ligament, and joint conditions (eg, rheumatoid arthritis, fibromyalgia)
- Bell palsy
- lymphedema
- chronic non-healing wounds

CODING

BlueCHiP for Medicare and Commercial Products

Providers should file the following HCPCS code, as there isn't a specific CPT code for the service.

The following code is covered when filed with the ICD-10 diagnosis codes below.

S8948 Application of a modality (requiring constant provider attendance) to one or more areas; low-level laser; each 15 minutes

ICD-10 CM: C00 - D49

RELATED POLICIES

Not applicable

PUBLISHED

Provider Update, December 2020

Provider Update, January 2020

Provider Update, September 2018

Provider Update, January 2018

Provider Update, January 2017

REFERENCES

1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*. May 15 2014;120(10):1453-1461. PMID 24615748
2. Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. *Support Care Cancer*. Oct 2007;15(10):1145-1154. PMID 17393191
3. Figueiredo AL, Lins L, Cattony AC, et al. Laser therapy in the control of oral mucositis: a meta-analysis. *Rev Assoc Med Bras (1992)*. Sep-Oct 2013;59(5):467-474. PMID 24119379
4. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. *PLoS One*. Sep 2014;9(9):e107418. PMID 25198431

5. Doeuk C, Hersant B, Bosc R, et al. Current indications for low level laser treatment in maxillofacial surgery: a review. *Br J Oral Maxillofac Surg*. Apr 2015;53(4):309-315. PMID 25740083
6. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - A triple blinded randomized controlled trial. *Radiother Oncol*. Sep 2012;104(3):349-354. PMID 22884841
7. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low Level Helium Neon Laser therapy for chemoradiotherapy induced oral mucositis in oral cancer patients - A randomized controlled trial. *Oral Oncol*. Sep 2012;48(9):893- 897. PMID 22502814
8. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck cancer patients receiving chemoradiotherapy--a randomized controlled trial. *Support Care Cancer*. May 2013;21(5):1421-1428. PMID 23224689
9. Gautam AP, Fernandes DJ, Vidyasagar MS, et al. Low level laser therapy against radiation induced oral mucositis in elderly head and neck cancer patients-a randomized placebo controlled trial. *J Photochem Photobiol B*. Mar 2015;144:51-56. PMID 25704314
10. Oton-Leite AF, Silva GB, Morais MO, et al. Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients. *Lasers Surg Med*. Apr 2015;47(4):296-305. PMID 25824475
11. Ferreira B, da Motta Silveira FM, de Orange FA. Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. *Support Care Cancer*. Mar 2016;24(3):1035-1042. PMID 26248655
12. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Low-level laser therapy for carpal tunnel syndrome and chronic neck pain. *TEC Assessment*. Nov 2010;Volume 25:Tab 4. PMID 21638940
13. Li ZJ, Wang Y, Zhang HF, et al. Effectiveness of low-level laser on carpal tunnel syndrome: A meta-analysis of previously reported randomized trials. *Medicine (Baltimore)*. Aug 2016;95(31):e4424. PMID 27495063
14. Fusakul Y, Aranyavalai T, Saensri P, et al. Low-level laser therapy with a wrist splint to treat carpal tunnel syndrome: a double-blinded randomized controlled trial. *Lasers Med Sci*. May 2014;29(3):1279-1287. PMID 24477392
15. Gross AR, Dziengo S, Boers O, et al. Low level laser therapy (LLLT) for neck pain: a systematic review and meta-regression. *Open Orthop J*. Oct 2013;7:396-419. PMID 24155802
16. Yeldan I, Cetin E, Ozdincler AR. The effectiveness of low-level laser therapy on shoulder function in subacromial impingement syndrome. *Disabil Rehabil*. Nov 2009;31(11):935-940. PMID 19031167
17. Dogan SK, Ay S, Evcik D. The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. *Clinics (Sao Paulo)*. Dec 2010;65(10):1019-1022. PMID 21120304
18. Abrisham SM, Kermani-Alghoraishi M, Ghahramani R, et al. Additive effects of low-level laser therapy with exercise on subacromial syndrome: a randomised, double-blind, controlled trial. *Clin Rheumatol*. May 4 2011;30(10):1341-1346. PMID 21538218
19. Bal A, Eksioglu E, Gurcay E, et al. Low-level laser therapy in subacromial impingement syndrome. *Photomed Laser Surg*. Feb 2009;27(1):31-36. PMID 19250050
20. Calis HT, Berberoglu N, Calis M. Are ultrasound, laser and exercise superior to each other in the treatment of subacromial impingement syndrome? A randomized clinical trial. *Eur J Phys Rehabil Med*. Mar 2 2011;47(3):375-380. PMID 21364511
21. Page MJ, Green S, Kramer S, et al. Electrotherapy modalities for adhesive capsulitis (frozen shoulder). *Cochrane Database Syst Rev*. Oct 1 2014;10:CD011324. PMID 25271097
22. Stergioulas A. Low-power laser treatment in patients with frozen shoulder: preliminary results. *Photomed Laser Surg*. Apr 2008;26(2):99-105. PMID 18341417
23. Chen J, Huang Z, Ge M, et al. Efficacy of low-level laser therapy in the treatment of TMDs: a meta-analysis of 14 randomised controlled trials. *J Oral Rehabil*. Apr 2015;42(4):291-299. PMID 25491183

24. Chang WD, Lee CL, Lin HY, et al. A meta-analysis of clinical effects of low-level laser therapy on temporomandibular joint pain. J Phys Ther Sci. Aug 2014;26(8):1297-1300. PMID 25202201
25. Shobha R, Narayanan VS, Jagadish Pai BS, et al. Low-level laser therapy: A novel therapeutic approach to temporomandibular disorder - A randomized, double-blinded, placebo-controlled trial. Indian J Dent Res. Jul-Aug 2017;28(4):380-387. PMID 28836528

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

